ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?

A A Thai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.